Vestal Point Capital, LP
Q1 2026 13F Holdings
- Locationnew york, NY
- Num holdings
90
- Value ($000)
$3,576,817
- Date Filed 05/15/2026
- Form type13F-HR
- CIK 0001974915
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q1 2026 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
Revolution Medicines Inc | COM | 76155X100 | $230.97M | 7 % | 2,375,000 | ||
BioMarin Pharmaceutical Inc | COM | 09061G101 | $201.95M | 6 % | 3,575,000 | ||
Abivax SA | SPONSORED ADS | 00370M103 | $167.03M | 5 % | 1,500,000 | ||
Neurocrine Biosciences Inc | COM | 64125C109 | $164.68M | 5 % | 1,250,000 | ||
Arrowhead Pharmaceuticals Inc | COM | 04280A100 | $142.64M | 4 % | 2,275,000 | ||
Enliven Therapeutics Inc | COM | 29337E102 | $127.4M | 4 % | 3,250,000 | ||
Repligen Corp | COM | 759916109 | $108.98M | 3 % | 925,000 | ||
Bicara Therapeutics Inc | COM | 055477103 | $107.9M | 3 % | 5,425,000 | ||
Nurix Therapeutics Inc | COM | 67080M103 | $100.75M | 3 % | 6,500,000 | ||
Apogee Therapeutics Inc | COM | 03770N101 | $92.59M | 3 % | 1,100,000 |
Rows Per Page
10
- 10
- 50
- 100